Robust preclinical results for live-attenuated SARS-CoV-2 vaccine
Live-attenuated SARS-CoV-2 vaccine candidate, OTS-228, has demonstrated exceptional safety, efficacy, and genomic stability in preclinical animal models.
The vaccine was developed under the scientific leadership of Professor Dr Volker Thiel, Chief Scientist of Rocketvax and Professor of Virology at the University of Bern.
The latest studies were conducted in collaboration with the Friedrich-Loeffler-Institut (FLI), Germany’s Federal Research Institute for Animal Health.
The general ability to induce transmission-blocking immunity and broad protection even against SARS-CoV-2 variants Omicron BA.2, BA.5, and XBB.1.5 was demonstrated previously.
The preclinical data were published in NPJ Vaccines.
Key findings:
- OTS-228 shows excellent safety and high efficacy in Syrian hamster models.
- Maximum dose trials confirm full attenuation and prevention of virus spread.
- Serial in vivo passages reveal no reversion to virulence and high genomic stability.
- Maintains efficacy and attenuation even after 15 in vitro passages.
- Protective dose 50 (PD₅₀) established at <100 TCID₅₀ per hamster in low-dose challenge infection.
“OTS-228 is the result of years of coronavirus research and rational vaccine design,” said Professor Thiel. “Live-attenuated vaccines can offer long-lasting and broad immunity, and our data show that OTS-228 has the potential to become a safe and effective tool against current and future SARS-CoV-2 variants.”
Dr Natasa Cmiljanovic, Chief Operating Officer of Rocketvax, added: “This successful collaboration with the University of Bern and the Friedrich-Loeffler-Institut has been pivotal. The robust preclinical results validate our live-attenuated vaccine platform and position Rocketvax to advance into clinical development. We are committed to making this innovative vaccine available as a global public health solution.”
Rocketvax has entered a strategic partnership with Emergent BioSolutions to commercialize Rocketvax vaccines in the US. The alliance leverages Emergent’s manufacturing infrastructure and regulatory experience to accelerate worldwide access to Rocketvax’s Covid-19 vaccine platform.
Diana Spencer, Senior Digital Content Editor, DDW
